Background
==========

Nephrolithiasis is a worldwide problem and affects almost all ethnicities and populations; most are calcium oxalate (CaOx) kidney stones. The prevalence rate in developed countries is between 4% and 20% \[[@b1-medscimonit-22-563]\]. The recurrence rate of nephrolithiasis is as high as 50% within 5 years \[[@b2-medscimonit-22-563]\]. Emerging studies have elucidated a series of events leading to formation of kidney stone \[[@b3-medscimonit-22-563]\]. Nephrolithiasis is affected by multiple risk factors, including environmental, hormonal, and genetic ones. The individuals with positive family history are predisposed to nephrolithiasis \[[@b1-medscimonit-22-563]\], which suggests that genetic factors may play a key role in development of kidney stone formation.

With the development of high-throughput transcriptome analyses, most of the human genome has been identified to be transcribed into noncoding RNAs. Different from the conventional coding genes, the noncoding RNAs play crucial roles in regulation of various physiological processes in the form of RNA, and do not have the ability to encode proteins. Long non-coding RNAs (lncRNAs) are a novel class of recently identified transcripts, which are transcribed pervasively in the genome and are involved in modulation of the epigenome \[[@b4-medscimonit-22-563]\]. LncRNAs can be roughly divided into five categories -- intronic lncRNAs, sense lncRNAs, antisense lncRNAs, bidirectional lncRNAs, and intergenic lncRNAs -- according to their relative position to the adjacent coding genes \[[@b5-medscimonit-22-563]\]. Among them, antisense lncRNAs have been reported to regulate function of corresponding coding genes at the post-transcriptional level \[[@b6-medscimonit-22-563]\]. However, much of the role of lncRNAs in nephrolithiasis remains unknown.

Located on 22q11.2, the macrophage migration inhibitory factor (*MIF*) gene encodes a multifunctional cytokine, MIF, generated from some types of cells, including epithelial cells \[[@b7-medscimonit-22-563],[@b8-medscimonit-22-563]\]. It has a key role in many kidney diseases. However, antisense transcript of MIF, named *MIF-AS* in the present study, was a novel unknown lncRNA. Studies on the biological function of *MIF-AS* and its role in nephrolithiasis have not been reported yet. Single-nucleotide polymorphism (SNP) mainly refers to the DNA sequence polymorphism at the genomic level caused by a single-nucleotide variation. Recent evidence has confirmed that SNPs in lncRNAs can affect its biological processes of mRNA formation, which may lead to the aberration of its interacting genes \[[@b9-medscimonit-22-563]--[@b11-medscimonit-22-563]\].

*MIF-AS* rs755622 has been shown to be associated with renal disease risk \[[@b12-medscimonit-22-563]\]. In the present study, we hypothesized that rs755622 located on exon of *MIF-AS* is involved in nephrolithiasis. Briefly, a total of 480 subjects, including 230 patients with nephrolithiasis and 250 healthy controls, were recruited to assess the association between the rs755622 polymorphism and nephrolithiasis risk.

Material and Methods
====================

Study subjects
--------------

This present study was approved by the Institutional Review Board of Huaiyin Hospital (Huai-An), and all subjects signed the informed consent form. The experimental protocol was carried out in accordance with the approved guidelines. There were 230 nephrolithiasis cases and 250 controls in this hospital-based case-control study. Briefly, all cases were confirmed to have nephrolithiasis at the time of enrollment in our ongoing study, and were recruited from Huaiyin Hospital (Huai-An) starting from March 2010, of which 91% had calcium oxalate kidney stones. Those people seeking general physical examinations at the outpatient department were recruited as the controls in the same hospital. Controls with renal diseases were excluded. Individuals who smoked daily for \>1 year were defined as smokers. The status of body mass index (BMI), hypertension, and diabetes were based on World Health Organization (WHO) standards. Informed consent was obtained from the eligible subjects before recruitment. Through face-to-face interview, individual demographics information was obtained.

Genotyping
----------

Genomic DNA was isolated from peripheral blood lymphocytes from cases and controls. The ABI 7900HT real-time PCR System (Applied Biosystems, Foster City, CA, USA) was used to conduct the TaqMan SNP genotyping assay. Two investigators implemented the genotype analysis independently. Approximately 10% of all the subjects were selected randomly for the verification of accuracy, which were totally consistent with the previous results.

Statistical analysis
--------------------

The Pearson's χ^2^ test and Student's t-test were applied to check the differences in the selected variables and distributions of demographic characteristics between cases and controls. Using adjusted odds ratios (ORs) and 95% confidence intervals (CIs) from unconditional logistic regression, we estimated the association between the nephrolithiasis risk and genotypes. Hardy-Weinberg equilibrium was used to calculate the genotype frequencies among the controls. The statistical analyses were conducted with SAS software (version 9.1, SAS Institute, Inc, Cary, NC, USA) and the differences were considered to be statistically significant when 2-sided *P*\<0.05.

Results
=======

Characteristics of study subjects
---------------------------------

[Table 1](#t1-medscimonit-22-563){ref-type="table"} present the demographic information of cases and controls enrolled in this study. The mean age of the nephrolithiasis patients was 46.7 years compared with 45.9 years in controls, which showed no significant difference (*P*=0.174). The sex distributions were similar (*P*=0.785) among cases and controls. However, there were more smokers among the cases than among the controls (*P*=0.001), suggesting that smoking may have an effect on the etiology of nephrolithiasis. Furthermore, no statistically significant differences were found in the distributions of BMI, hypertension status, diabetes, and drinking status between cases and controls.

Association between *MIF-AS* rs755622 polymorphism and nephrolithiasis risk
---------------------------------------------------------------------------

The genotype distributions of *MIF-AS* rs755622 in 480 subjects are shown in [Table 2](#t2-medscimonit-22-563){ref-type="table"}. The genotype frequency conformed to Hardy-Weinberg equilibrium in controls (*P*=0.473). The frequency of rs755622 GC/CC genotypes was significantly higher among cases than among controls (52.2% *vs*. 41.2%, *P*=0.016). We evaluated the association between rs755622 and nephrolithiasis risk by unconditional logistic regression. In the additive model, individuals with the CT and CC genotype had significantly increased nephrolithiasis risk (adjusted OR=1.52, 95% CI=1.03--2.25; OR=2.63, 95% CI=1.21--5.72, *P*=0.015) than those with GG genotype, as presented in [Table 2](#t2-medscimonit-22-563){ref-type="table"}. In addition, compared with those carrying GG genotype, the rs755622 C carriers (GC/CC) had an adjusted OR (95% CI) of 1.65 (1.14--2.39, *P*=0.016) in the dominant model.

Furthermore, we conducted stratified analyses of sex, age, BMI, hypertension status, drinking, and smoking status. As presented in [Table 3](#t3-medscimonit-22-563){ref-type="table"}, when the rs755622 GG genotype was regarded as the reference, the increased risk of nephrolithiasis for GC/CC genotypes was also found among subgroup age \>46 (adjusted OR=2.12, 95% CI=1.23--3.66, *P*=0.007), male (adjusted OR=1.82, 95% CI=1.15--2.90, *P*=0.001), BMI \>24 (adjusted OR=2.50, 95% CI=1.44--4.34, *P*=0.001), hypertension patients (adjusted OR=1.94, 95% CI=1.27--2.97, *P*=0.002), smoking (adjusted OR=1.94, 95% CI=1.05--5.59, *P*=0.034), and drinking (adjusted OR=2.44, 95% CI=1.31--4.54, *P*=0.005).

*In silico* analysis of rs755622 on *MIF-AS* folding
----------------------------------------------------

It is plausible that rs755622 may disrupt the function of *MIF-AS* by influencing its dimensional folding structure, because the rs755622 locates at the exon region of *MIF-AS*. The local structure change of *MIF-AS* caused by rs755622 was predicted through RNAfold \[[@b13-medscimonit-22-563]\] and SNPfold \[[@b14-medscimonit-22-563]\] algorithms. Indeed, the SNP rs755622 changed the folding structures of *MIF-AS,* as shown in [Figure 1](#f1-medscimonit-22-563){ref-type="fig"}.

Discussion
==========

Genetic variations are involved in the development and progression of nephrolithiasis \[[@b15-medscimonit-22-563]\]. The *MIF-AS* rs755622 was associated with renal disease risk \[[@b12-medscimonit-22-563]\], which suggests that it may participate in development of nephrolithiasis. In this study, we hypothesized that rs755622 located on exon of *MIF-AS* is involved in nephrolithiasis. Briefly, a total of 480 subjects, including 230 patients with nephrolithiasis and 250 healthy controls, were recruited to assess the association between the rs755622 polymorphism and nephrolithiasis risk.

The results showed that individuals with the rs755622 genotypes (GC/CC) had a significantly increased nephrolithiasis risk compared with those carrying the GG genotype. In addition, we also confirmed the association between the SNP rs755622 and age \>46, male, BMI \>24, hypertension, and smoking in the development of nephrolithiasis. Moreover, we identified that the SNP rs755622 may lead to abnormal function of *MIF-AS* by modifying its folding structures.

Studies have found the MIF is a multifunctional cytokine, which is secreted from endothelial cells, macrophages, T lymphocytes, and other inflammatory cells \[[@b16-medscimonit-22-563]--[@b18-medscimonit-22-563]\]. MIF has been identified to participate in a variety of inflammatory and immune response-related conditions, including ankylosing spondylitis \[[@b19-medscimonit-22-563]\], ocular inflammation \[[@b20-medscimonit-22-563]\], and rheumatoid arthritis \[[@b21-medscimonit-22-563]\]. In addition, it is also involved in many kidney diseases. Brown et al. that revealed urine MIF level was correlated with kidney MIF protein and was up-regulated in patients with acute renal rejection \[[@b22-medscimonit-22-563]\]. Elevated circulating MIF was detected in end-stage renal disease patients but not in healthy controls \[[@b23-medscimonit-22-563]\]. A case-control study showed that patients with end-stage renal disease with *MIF* rs755622 CC genotype had 8-fold higher MIF expression compared with healthy individuals \[[@b24-medscimonit-22-563]\], suggesting that rs755622 may have a key role in development of kidney diseases. However, few studies have investigated the role of *MIF-AS* rs755622 and its influence on *MIF-AS* function in the development of nephrolithiasis.

LncRNAs are a crucial class of pervasive genes involved in various important biologic processes \[[@b25-medscimonit-22-563]\]. However, how genetic variations in lncRNAs contribute to nephrolithiasis predisposition has not been elucidated. Many studies have reported that variations of the key regulatory locus of an RNA molecule can severely disturb its function \[[@b14-medscimonit-22-563]\], which shows that SNPs may be one of the key mechanisms effecting function of lncRNAs. Considering the crucial role of antisense lncRNAs in regulating their neighboring coding genes, we hypothesized that this antisense lncRNA *MIF-AS* may take part in nephrolithiasis through regulating the function of *MIF*. Based on the results of this study, our findings provide a plausible theoretical foundation for our hypothesis *in silico*, as shown in [Figure 1](#f1-medscimonit-22-563){ref-type="fig"}. It is biologically plausible that SNP rs755622 further changes the interactions between the *MIF-AS* and *MIF*.

We found that rs755622 is also located on the CpG island of *MIF* promoter by using the public dataset UCSC (*<http://genome.ucsc.edu/>*). The SNP rs755622G\>C changes the DNA sequence GG of *MIF* promoter to CG, a CpG site. The methylation of promoter CpG islands is an important gene regulatory mechanism. Hypermethylation of gene promoter often represses its expression. A genetic variation in *MIF* promoter could affect the combination of transcription factors and modulate its expression. Moreover, the SNPs in the promoter may also eliminate or create CpG sites by which gene expression is suppressed or promoted. As this study indicated, the SNP rs755622G\>C created a CpG site, which may influence the methylation of *MIF* promoter. We thus propose that individuals with the rs755622 genotypes (GC/CC) had significantly increased nephrolithiasis risk compared with those carrying the GG genotypes because of aberrant methylation of *MIF* promoter, but his hypothesis requires confirmation in functional studies.

Because kidney stone formation is a complex process, it is impossible that any single SNP or gene exerts a remarkable influence on nephrolithiasis risk. Finally, there was a limitation of our study. Although we demonstrated a dramatic association between the SNP rs755622 and nephrolithiasis risk, how this genetic variation influences the biological function of *MIF-AS* needs to be fully elucidated. According to a previous study by Faghihi et al., antisense lncRNA may regulate the expression of coding genes by increasing mRNA stability \[[@b26-medscimonit-22-563]\]. Investigation on this association between *MIF-AS* and *MIF* will be conducted in further studies.

Conclusions
===========

We provided the initial evidence that individuals with the SNP rs755622 GC/CC had a significantly increased nephrolithiasis risk compared to those with the GG genotype, indicating that the C allele has a deleterious effect on nephrolithiasis risk. The results revealed that the *MIF-AS* rs755622 may act as a candidate marker to predict the nephrolithiasis risk in Chinese populations. Lastly, we proposed a hypothesis that rs755622 participates in the development of nephrolithiasis by modulating the function of *MIF* and lncRNA *MIF-AS*. Further large well-designed functional studies in other independent populations are needed.
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![Influence of rs755622 on *MIF-AS* local folding structures. The local structure changes were illustrated by RNAfold (**A**) and SNPfold (**B**), respectively. The arrow (**A**) indicates the position of rs755622. The black line (**B**) represents the SNP rs755622 G allele sequences, whereas the red line represents the C allele. The blue line (**B**) indicates the position of rs755622.](medscimonit-22-563-g001){#f1-medscimonit-22-563}

###### 

The characteristics description of kidney stone and controls.

  Variables         Cases n=230 (%)   Controls n=250 (%)   *P*^\*^
  ----------------- ----------------- -------------------- ---------
  Age (years)       46.7±12.5         45.9 ±12.5           
   ≤46              109 (47.4)        134 (53.6)           0.174
   \>46             121 (52.6)        116 (46.4)           
  Sex                                                      
   Male             150 (65.2)        166 (66.4)           0.785
   Female           80 (34.8)         84 (33.6)            
  BMI                                                      
    ≤24             111 (48.3)        127 (50.8)           0.578
   \>24             119 (51.7)        123 (49.2)           
  Hypertension                                             
   Yes              59 (25.7)         46 (18.4)            0.055
   No               171 (74.3)        204 (81.6)           
  Diabetes                                                 
   Yes              17 (7.4)          19 (7.6)             0.931
   No               213 (92.6)        231 (92.4)           
  Smoking status                                           
   Ever             103 (44.8)        76 (30.4)            0.001
   Never            127 (55.2)        174 (69.6)           
  Drinking status                                          
   Ever             88 (38.3)         93 (37.2)            0.811
   Never            142 (61.7)        157 (62.8)           

###### 

Genotype and allele frequencies of MIF rs755622 among cases and controls and their associations with kidney stone risk.

  MIF rs755622   Cases (n=230)   Controls (n=250)   *P*[\*](#tfn1-medscimonit-22-563){ref-type="table-fn"}   OR (95% CI)[\*\*](#tfn2-medscimonit-22-563){ref-type="table-fn"}
  -------------- --------------- ------------------ -------------------------------------------------------- ------------------------------------------------------------------
  GG             110             147                0.015                                                    1.57 (1.16--2.12)
  GC             98              92                                                                          1.52 (1.03--2.25)
  CC             22              11                                                                          2.63 (1.21--5.72)
  GC+CC          120             103                0.016                                                    1.65 (1.14--2.39)
  GG+GC          208             239                                                                         1.00 (ref.)
  CC             22              11                 0.026                                                    2.21 (1.03--4.71)
  Trend                                             0.005                                                    

*P* for two-sided χ^2^ test;

Adjusted for age, sex and smoking status in logistic regression model.

###### 

Stratification analyses of MIF rs755622 SNP association with kidney stone risk.

  Characteristics   Cases (n=230)   Controls (n=250)   OR (95% CI)a   *P*[\*](#tfn3-medscimonit-22-563){ref-type="table-fn"}   *P*[\*\*](#tfn4-medscimonit-22-563){ref-type="table-fn"}               
  ----------------- --------------- ------------------ -------------- -------------------------------------------------------- ---------------------------------------------------------- ----------- -------
  Age (years)                                                                                                                                                                                         
   ≤46              55              54                 75             59                                                       1.32 (0.78--2.21)                                          0.300       0.221
   \>46             55              66                 72             44                                                       **2.12 (1.23--3.66)**                                      **0.007**   
  Sex                                                                                                                                                                                                 
   Male             67              83                 95             71                                                       **1.82 (1.15--2.90)**                                      **0.001**   0.663
   Female           43              37                 52             32                                                       1.51 (0.79--2.87)                                          0.213       
  BMI                                                                                                                                                                                                 
   ≤24              57              54                 70             57                                                       1.12 (0.66--1.91)                                          0.676       0.115
   \>24             53              66                 77             46                                                       **2.50 (1.44--4.34)**                                      **0.001**   
  Hypertension                                                                                                                                                                                        
   Yes              35              24                 27             19                                                       **1.94 (1.27--2.97)**                                      **0.002**   0.163
   No               75              96                 120            84                                                       1.46 (0.89--3.65)                                          0.413       
  Smoking status                                                                                                                                                                                      
   Ever             48              55                 48             28                                                       **1.94 (1.05--3.59)**                                      **0.034**   0.367
   Never            62              65                 99             75                                                       1.55 (0.96--2.48)                                          0.072       
  Drinking status                                                                                                                                                                                     
   Ever             35              53                 55             38                                                       **2.44 (1.31--4.54)**                                      **0.005**   0.151
   Never            75              67                 92             65                                                       1.35 (0.85--2.16)                                          0.206       

Adjusted for age, sex and smoking status in logistic regression model;

*P* for heterogeneity test.
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